Aurobindo Pharma Limited

NSEI:AUROPHARMA 株式レポート

時価総額:₹717.5b

Aurobindo Pharma バランスシートの健全性

財務の健全性 基準チェック /56

Aurobindo Pharmaの総株主資本は₹308.8B 、総負債は₹80.9Bで、負債比率は26.2%となります。総資産と総負債はそれぞれ₹480.9Bと₹172.1Bです。 Aurobindo Pharmaの EBIT は₹49.8Bで、利息カバレッジ比率63.2です。現金および短期投資は₹68.7Bです。

主要情報

26.2%

負債資本比率

₹80.91b

負債

インタレスト・カバレッジ・レシオ63.2x
現金₹68.68b
エクイティ₹308.85b
負債合計₹172.09b
総資産₹480.94b

財務の健全性に関する最新情報

Recent updates

Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Nov 12
Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Oct 20
Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Sep 10
Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Aug 23
This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Aug 13
Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Jun 20
Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29
Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

May 22
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Apr 10
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Jan 14
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Dec 27
Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 07
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Jun 14
Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

May 21
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Feb 11
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Jan 09
Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

Nov 02
Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Jun 20
We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

財務状況分析

短期負債: AUROPHARMAの 短期資産 ( ₹262.3B ) が 短期負債 ( ₹143.4B ) を超えています。

長期負債: AUROPHARMAの短期資産 ( ₹262.3B ) が 長期負債 ( ₹28.7B ) を上回っています。


デット・ツー・エクイティの歴史と分析

負債レベル: AUROPHARMAの 純負債対資本比率 ( 4% ) は 満足できる 水準であると考えられます。

負債の削減: AUROPHARMAの負債対資本比率は、過去 5 年間で37.2%から26.2%に減少しました。

債務返済能力: AUROPHARMAの負債は 営業キャッシュフロー によって 十分にカバーされていません ( 19.6% )。

インタレストカバレッジ: AUROPHARMAの負債に対する 利息支払いEBIT ( 63.2 x coverage) によって 十分にカバーされています


貸借対照表


健全な企業の発掘